Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01822509
Title Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

multiple myeloma

hematologic cancer

Hodgkin's lymphoma

chronic myeloid leukemia

acute leukemia

myelodysplastic syndrome

non-Hodgkin lymphoma

myelodysplastic/myeloproliferative neoplasm

chronic lymphocytic leukemia

Therapies

Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.